Colorectal cancer, systemic inflammation, and outcome: Staging the tumor and staging the host

Annals of Surgery

Volumn 263, Issue 2, 2016, Pages 326-336

  Park, James H ^a   Watt, David G ^a   Roxburgh, Campbell S D ^a   Horgan, Paul G ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Colorectal cancer; modified Glasgow Prognostic Score; Prognosis; Survival; Systemic inflammation

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLORECTAL CANCER; COLORECTAL CARCINOMA; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCORING SYSTEM; ADENOCARCINOMA; COLORECTAL NEOPLASMS; COMPLICATION; FACTUAL DATABASE; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84955731714     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001122     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Fleming ID. American Joint Committee on Cancer, American Cancer Society. In: AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
3. Horgan PG, McMillan DC. Surgeons and selection of adjuvant therapy for node-negative colonic cancer. Br J Surg. 2010;97:1459-1460.
4. Oliphant R, Mansouri D, Nicholson GA, et al. Emergency presentation of node-negative colorectal cancer treated with curative surgery is associated with poorer short and longer-term survival. Int J Colorectal Dis. 2014;29:591-598.
5. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-540.
6. Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218-230.
7. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633-2641.
8. Leitch EF, Chakrabarti M, Crozier JEM, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266-1270.
9. Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, et al. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2013;109:24-28.
10. Choi KW, Hong SW, Chang YG, et al. Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014;86:309-313.
11. Powell AG, Wallace R, McKee RF, et al. The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Dis. 2012;14:1493-1499.
12. Richards CH, Leitch EF, Horgan PG, et al. The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2010;103: 1356-1361.
13. Roxburgh CSD, Platt JJ, Leitch EF, et al. Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol. 2011;18:997-1005.
14. Mohri Y, Miki C, Kobayashi M, et al. Correlation between preoperative systemic inflammation and postoperative infection in patients with gastroin-testinal cancer: a multicenter study. Surg Today. 2014;44:859-867.
15. Roxburgh C, McDonald A, Salmond J, et al. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis. 2011;26:483-492.
16. Michigan A, Johnson TV, Master VA. Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma. Mol Diagn Ther. 2011;15:229-234.
17. Sharma R, Zucknick M, London R, et al. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7:331-337.
18. Loughrey MB, Quirke P, Shepherd NA. Dataset for Colorectal Cancer Histopathology Reports. 3rd ed, London, UK: The Royal College of Pathol-ogists; 2014.
19. Morris EJ, Maughan NJ, Forman D, et al. Who to treat with adjuvant therapy in Dukes B(stage II colorectal cancer? The need for high quality pathology. Gut. 2007;56:1419-1425.
20. Mansouri D, McMillan DC, Crighton EM, et al. Screening for colorectal cancer: what is the impact on the determinants of outcome? Crit Rev Oncol Hematol. 2013;85:342-349.
21. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717-727.
22. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40:685-691.
23. McMillan DC, Wigmore SJ, Fearon K, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer. 1999;79:495-500.
24. Park JH, McMillan DC, Horgan PG, et al. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 2014;40:68-77.
25. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110:1409-1412.